For EGFR pathways, apart from directly targeting EGFR for NPC treatment, targeting DLC-1, as well as a combination of EGFR targeting inhibitors with chemoradiotherapy may be potential therapeutic strategies for NPC. This evidence concerns the gene EGFR and nasopharyngeal carcinoma.